Table 1 shows that a substantial amount of variation in high priority regions for addiction is currently unaccounted for by these commercial microarrays. Ultimately, the actual number of SNPs used to supplement a microarray will depend on the genotyping platform being used for supplementation. This platform could involve a different technology than that of the original microarray being supplemented. For example, the Affymetrix 6.0 array could be supplemented with custom genotyping on the Illumina GoldenGate platform (http://www.illumina.com), and because some of the SNPs used for Table 1 may not perform well on the GoldenGate platform, the numbers reported in the table may need to be reduced.
